Together, suggest that high local or systemic IL-1β plus CXCL1 plus CCL2 plus S100A8 plus VEGF plus IL8 in breast cancer patients represents a diagnostic biomarker for the existence of IRISOE TNBC tumor, and propensity to reduced RFS, DMFS, or OS. This evidence concerns the gene CXCL8 and breast carcinoma.